Proteins and Peptides

1 August 2024

Lilly’s tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity

31 July 2024

Connext Successfully Administers First Dose of CNT201 for Dupuytren’s Contracture

31 July 2024

CinFina Pharma Announces Initiation of Phase 1 Multiple Ascending Dose (MAD) Clinical Trial of CIN-110 for the Treatment of Obesity

30 July 2024

INmune Bio Inc. Announces New Phase 1 Study Data Demonstrating Dose-Dependent Effect of XPro™ on Proteins that Regulation Synapses in Alzheimer’s Patients

30 July 2024

Galderma’s Relfydess™ (RelabotulinumtoxinA) Receives Positive Decision for Use in Europe

25 July 2024

U.S. Food and Drug Administration Approves BioMarin’s BRINEURA® (cerliponase alfa) for Children Under 3 Years with CLN2 Disease

24 July 2024

Rhythm Pharmaceuticals Announces First Patients Dosed in Phase 2 Trial Evaluating Oral MC4R Agonist LB54640 in Hypothalamic Obesity

23 July 2024

Blue Earth Therapeutics Announces Clinical Research Collaboration with UCL to Develop Innovative Alpha-labelled Radioligand Therapy (RLT) for Prostate Cancer

23 July 2024

Gan & Lee Pharmaceuticals’ Bi-weekly (twice a month) GLP-1 Receptor Agonist GZR18 Injection Achieved 17.29% Weight Loss at 30 Weeks in a Phase IIb Clinical Trial

23 July 2024

Cytoki Pharma Announces Positive Phase 1 Data Showing Potential of CK-0045 to Improve Cardiometabolic Risk Factors

19 July 2024

GRO Biosciences Closes $60M Series B Financing Co-Led by Atlas Venture and Access Biotechnology

17 July 2024

NGM Bio Announces $122 Million Series A Financing to Initiate Registrational Trial in Primary Sclerosing Cholangitis and Fund Phase 2 Trial in Hyperemesis Gravidarum

16 July 2024

NexThera Files IND Application for Phase 1/2a Clinical Trial of NT-101 Eye Drop for Wet AMD

15 July 2024

Cytonics Announces Initiation Of First-In-Human Phase 1 Clinical Study For CYT-108 In Patients Suffering From Osteoarthritis Of The Knee

15 July 2024

Ferring Presents Early Response Data From Pivotal Phase 3 Trial for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASPN 2024

15 July 2024

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

12 July 2024

Vivani Medical Provides Update on Clinical Development Plans for Miniature, Long-term, GLP-1 Obesity Implant Program, NPM-115

11 July 2024

Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation

10 July 2024

AEON Biopharma Announces Strategic Reprioritization to Pursue a Biosimilar Pathway for ABP-450

3 July 2024

Sobi initiates rolling biologics license application to FDA for SEL-212 for the potential treatment of chronic refractory gout

28 June 2024

Elicio Therapeutics Announces Preliminary Disease-Free Survival analysis from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P

27 June 2024

Oncopeptides selects first candidate drug from its SPiKE platform

26 June 2024

Savara Announces Molgramostim Nebulizer Solution (Molgramostim) Achieved Statistical Significance for Primary Endpoint and Multiple Secondary Endpoints in IMPALA-2, a Pivotal Phase 3 Clinical Trial in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

26 June 2024

TwoStep Therapeutics Launches with Funding to Advance Broadly Applicable Targeting Platform for Solid Tumors

25 June 2024

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

25 June 2024

TiumBio Presents Promising Clinical Data from Phase 1 of its Hemophilia Treatment Candidate TU7710 at ISTH 2024

25 June 2024

Ozempic® (semaglutide) injection 1 mg demonstrated reduction in risk of kidney disease-related events in Phase 3 FLOW trial presented at the 84th Scientific Sessions of the American Diabetes Association

25 June 2024

Innovent Presents the Results of the First Phase 3 Study of Mazdutide for Weight Management at the ADA’s 84th Scientific Sessions

23 June 2024

Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association’s 84th Scientific Sessions

23 June 2024

Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association’s 84th Annual Scientific Sessions

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Adalimumab (Humira) Biosimilars Pipeline Review

Her3-Targeted Immunotherapy Pipeline Review

Claudin 18.2-Targeted Immunotherapeutics – a Competitor Analysis

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

CCR8-Targeted Antibody Immunotherapy Pipeline Review

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

Report Package: Bispecific Antibodies

B7-H3-Targeted Immunotherapy Candidates Pipeline Review

Report Package: Claudin 18.2-Targeted Immunotherapeutics

Vectorized Antibodies for In Vivo Expression by DNA and mRNA: a landscape analysis of stakeholders, technologies, targets, business and financing from an industry perspective